In Vivo Characterization of Helper-dependent Adenoviral Vectors Expressing Human LRRK2
MJFF Research Grant, 2012
Mutations in the LRRK2 gene are a common cause of familial Parkinsonís disease. Familial LRRK2 mutations induce neuronal toxicity in vitro. Reliable pre-clinical models of LRRK2-induced neurodegeneration do not currently exist. However, we have successfully developed a model of G2019S LRRK2-induced dopaminergic neurodegeneration by adenoviral-mediated gene transfer. This project aims to characterize and optimize new helper-dependent human adenoviral serotype 5 (Hd-Ad5) vectors for expressing human LRRK2 in vivo in the nigrostriatal pathway.
The MJFF have recently developed Hd-Ad5 vectors for expressing full-length human LRRK2 variants or GFP in the nigrostriatal pathway of pre-clinical models by viral-mediated gene transfer. Here, we will characterize these new Hd-Ad5 vectors for use in vivo by demonstrating high-level and equivalent expression of LRRK2 variants following intrastriatal delivery. We will establish the optimal dose of virus for efficient transduction of the striatum and retrograde transport to substantia nigra dopaminergic neurons. Hd-Ad5 vectors will then be used to confirm the pathogenic effects of the familial G2019S LRRK2 by inducing progressive dopaminergic degeneration relative to wild-type LRRK2 and GFP expression. Furthermore, the contribution of kinase activity to this process will be determined by using a kinase-dead version of G2019S LRRK2. Our studies aim to establish Hd-Ad5-mediated LRRK2 delivery as a robust pre-clinical model of Parkinsonís disease, and the contribution of kinase activity to LRRK2-dependent neurdegeneration.
Relevance to Diagnosis/Treatment of Parkinsonís Disease:†††††††††††††††††††††
These studies will develop a pre-clinical model of Parkinsonís disease (PD) with dopaminergic neurodegeneration based upon the expression of the most common disease-associated LRRK2 mutation, G2019S. This model will help to understand the underlying mechanism of neurodegeneration induced by LRRK2 familial mutations and may provide a valuable pre-clinical model for evaluation of LRRK2-based therapeutics for treating PD.†
This project will evaluate the progressive dopaminergic neurodegeneration induced by the Hd-Ad5-mediated expression of G2019S LRRK2 in a pre-clinical brain and the contribution of kinase activity to the pathological effects of mutant LRRK2. These studies will guide the development of future therapies based upon modulating LRRK2 activity.
Professor in the Department of Neuroscience at University of Florida College of Medicine
Location: Gainesville, Florida, United States
Associate Professor, Center for Neurodegenerative Science and Head, Laboratory of Molecular Neurodegeneration at Van Andel Research Institute
Location: Grand Rapids, Michigan, United States
Discover More Grants
Within the Same Program
Within the Same Funding Year